Novo Nordisk A/S is a global healthcare company focused on developing and manufacturing innovative pharmaceuticals, primarily in the fields of diabetes care and hormone replacement therapy. With a strong emphasis on research and development, the company aims to improve the lives of patients with chronic conditions by providing high-quality medications and medical devices. Novo Nordisk is recognized for its comprehensive approach to diabetes management, including insulin products and modern delivery systems, while also expanding its portfolio to address other serious conditions, such as obesity and rare blood disorders. The company operates in numerous countries, combining expertise in biotechnology with a commitment to sustainability and corporate responsibility. Read More
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility.
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential.
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517.
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?
However, Morgan Stanley sees limited impact on Lilly from the CMS decision as the proposed coverage appeared to apply only to a subset of the Medicare obesity population
Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic drug market may be negatively affected.
The company said that its earnings consist of income from dividends and the share repurchase programmes of Novo Group companies Novo Nordisk A/S and Novonesis A/S, as well as returns from its investment portfolio.
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform.
